| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_175bc6a075588ad56e84f22b391c7223 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 |
| filingDate |
2020-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5171488712d5173c27e7f8373ebed81b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45edf3f40392e7bc6c0d699ce474b44a |
| publicationDate |
2022-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112022004477-A2 |
| titleOfInvention |
Immunotherapy for the treatment of prostate cancer |
| abstract |
immunotherapeutic for the treatment of prostate cancer. the present disclosure describes a gnrh therapeutic for neutralizing gnrh levels in subjects that can reduce testosterone levels to attenuate or eliminate the growth and/or metastasis of prostate cancer cells. the therapeutic is produced synthetically. a gnrh therapeutic includes a hapten transporter (hc) comprising a monomeric peptide (mp), synthesized separately from the gnrh peptide, and after self-assembly of the hc, the gnrh is covalently coupled to form a gnrh-hc conjugate that can serve as a a therapeutic. mp includes seven-fold repeats following a specific pattern. the hc may include a gnrh peptide linked to a monomeric peptide prior to self-assembly to form a therapeutic. optionally, the gnrh-hc conjugate further includes one or more t-cell epitopes at the n and/or c-terminus of one or more amphipathic alpha helices. the present disclosure also describes compositions including immunogenic compositions including the therapeutics described herein. |
| priorityDate |
2019-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |